Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Croda signs vaccine adjuvant partnerships

by Craig Bettenhausen
May 25, 2023 | A version of this story appeared in Volume 101, Issue 17

 

Croda’s pharmaceutical division has signed two deals to shore up the supply chain for vaccine adjuvants, which are ingredients that enhance medicines’ performance. The synthetic biology firm Amyris will supply Croda with fermentation-derived squalene, which boosts immune response. Croda will also work with the tissue culture specialist Botanical Solution to make an immune-system-stimulating triterpene glycoside called QS-21. Botanical’s method avoids the destruction of soapbark (Quillaja saponaria), a rare Chilean evergreen tree.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.